Humana Inc. (NYSE:HUM) Given Average Recommendation of “Hold” by Analysts

Shares of Humana Inc. (NYSE:HUM) have earned an average rating of “Hold” from the twenty-four research firms that are currently covering the company, Marketbeat Ratings reports. Seventeen investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $286.81.

A number of analysts have recently weighed in on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $283.00 target price on shares of Humana in a report on Wednesday, February 12th. Truist Financial dropped their target price on shares of Humana from $325.00 to $305.00 and set a “hold” rating for the company in a report on Monday. Barclays increased their target price on shares of Humana from $270.00 to $322.00 and gave the stock an “equal weight” rating in a report on Friday, April 11th. StockNews.com upgraded shares of Humana from a “hold” rating to a “buy” rating in a report on Friday, May 9th. Finally, Morgan Stanley cut their target price on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 12th.

Humana Price Performance

Shares of NYSE:HUM opened at $230.28 on Friday. The stock has a market cap of $27.79 billion, a PE ratio of 23.14, a PEG ratio of 2.05 and a beta of 0.49. The company’s fifty day moving average is $263.70 and its 200 day moving average is $269.85. Humana has a 52 week low of $213.31 and a 52 week high of $406.46. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, topping analysts’ consensus estimates of $10.07 by $1.51. The company had revenue of $32.11 billion for the quarter, compared to analysts’ expectations of $32 billion. Humana had a net margin of 1.02% and a return on equity of 11.70%. The firm’s revenue was up 8.4% compared to the same quarter last year. During the same quarter last year, the company earned $7.23 EPS. Research analysts anticipate that Humana will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be issued a $0.885 dividend. The ex-dividend date is Friday, June 27th. This represents a $3.54 annualized dividend and a yield of 1.54%. Humana’s dividend payout ratio (DPR) is presently 25.04%.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. FPC Investment Advisory Inc. purchased a new position in Humana in the fourth quarter worth about $27,000. Centricity Wealth Management LLC purchased a new position in Humana in the fourth quarter worth about $30,000. Cary Street Partners Investment Advisory LLC raised its holdings in Humana by 63.9% in the first quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock worth $31,000 after buying an additional 46 shares during the last quarter. LFA Lugano Financial Advisors SA raised its holdings in Humana by 56.3% in the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock worth $32,000 after buying an additional 45 shares during the last quarter. Finally, Riverview Trust Co purchased a new position in Humana in the first quarter worth about $34,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.